3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
5
Cholangiocarcinoma
4
Stomach Neoplasms
2
Rectal Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Ovarian Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Interventions
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Folfox protocol
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts